Hoboken, NJ, Rostock/Berlin, Germany, February 22, 2022 – (ACN Newswire) – Based on Whole Genome Sequencing (WGS), Arcensus GmbH enables the detection of rare and common diseases such as cancer or heart disease at the earliest stage in order to start with a preventive and start personalized treatment.
A year after Arcensus was founded, fresh capital is now being raised for further expansion. As part of the current investment series, the Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) is investing a single-digit million amount in further expansion in the USA and the GCC region.
It is a very special investment for MBMV, as managing director Dr. Thomas Drews reveals: “With Arcensus, we are investing in a very experienced and well-known team and in a technology that, in this combination, has the potential to make a significant contribution to the prevention of diseases and the healing of rare diseases”.
He continues: “We are also proud that a local company from Rostock can play as a figurehead at the forefront of the international biotech scene.”
In fact, the team around Prof. Dr. Arndt Rolfs is no stranger to the biotech scene. Prof. Dr. Arndt Rolfs, a neurologist, listed his rare disease company CENTOGENE, founded in 2006, in 2019, in which MBMV also held shares.
At Arcensus, Prof. Rolfs and his international team want to use the accumulated experience in the field of WGS technology in combination with a clear focus on the groundbreaking, artificial intelligence (AI) based deep interpretation of DNA information to enable customers to do so best insight into preventable diseases.
Prof. Rolfs commented on the investment as follows: “We are very pleased to have a well-known partner and extremely trustworthy partner at our side in MBMV, who shares our vision: to empower people with genomic and medical knowledge to understand their health and to achieve a great and lasting quality of life and save lives”.
About Arcensus
Arcensus is a digital health and diagnostics company that empowers people to take control of their health. The company offers a safe, trusted and comprehensive medical service of the highest quality based on whole genome sequencing. Arcensus analyzes the complete genetic information in the human DNA and uses the latest technology including artificial intelligence to identify the predispositions and reasons for unclear symptoms. The detailed medical report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life. From our offices in New Jersey (USA), Rostock and Berlin (Germany), a cross-functional team of genetic experts, physicians and data scientists work to bring the most sophisticated and best genetic interpretation with medical and preventive health applications to everyone. For more information visit https://arcensus-diagnostics.com/.
About the medium-sized investment company Mecklenburg-Vorpommern (MBMV)
The Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH supports the promotion of regional SMEs by providing capital for the implementation of economic projects. It helps small and medium-sized companies in the region to consolidate or expand their market position. In particular, innovative companies with a national or international focus benefit from the flexible financing offer. For more information visit: https://www.mbm-v.de/beteiligung/
© Scoop Media
/cloudfront-us-east-2.images.arcpublishing.com/reuters/3PU3BNQZ4JPEJLD3DDIR7A5YZE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/26R37BQTE5P4BLJNJCC2VVXSJY.jpg)